shortage of glp 1 FDA Ends Semaglutide Listing, Contributing to Ongoing Legal Challenges FDA finalizes decision to end

Investigators such as Maquart et al

It has a fuller preclinical record plus clinical trial data tied to its approved indication [2, 3, 4]

Hair Growth, Hair Loss, and Hair Follicle Biology Hair growth claims are less established than topical skin claims

- if suppression of gastric acidity is still required then could it be managed with an H2 antagonist such as ranitidine (there is a general belief that they cause less nutritional harm than proton pump inhibitors)

Neither has been tested in humans, and both carry significant unknowns -- Dihexa with its retracted publication and oncological pathway concerns, PE-22-28 with its untested cognitive effects and potential seizure susceptibility